Advertisement

Topics

Sanofi buys rights to Principia’s BTK inhibitor

04:18 EST 10 Nov 2017 | PharmaTimes

Sanofi has bought itself rights to Principia BioPharma’s experimental tyrosine kinase (BTK) inhibitor PRN2246, in a deal potentially worth more than $800 million to the latter firm.

Original Article: Sanofi buys rights to Principia’s BTK inhibitor

NEXT ARTICLE

More From BioPortfolio on "Sanofi buys rights to Principia’s BTK inhibitor"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...